Background: HIV, hepatitis C (HCV), and human T-cell lymphotropic virus I (HTLV-1) are
associated with high global burdens of disease, notably in resource-poor locales. They …

Background: Chronic viral hepatitis is a potentially important determinant of health care
utilization among persons living with HIV. We describe hospitalization rates and reasons for …

Objectives: HIV, hepatitis C virus (HCV), and human T-cell lymphotropic virus type 1 (HTLV-
1) share the same routes of infection, making coinfection by these viruses a frequent finding …

To compare the impact of hepatitis C virus (HCV) coinfection on progression of HIV infection
in the eras before and after the introduction of highly active antiretroviral therapy (HAART) …

Background: Reports are mixed as to whether highly active antiretroviral therapy (HAART)
increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected …

Objectives: To assess incidence, risk factors, histology, and outcome of severe
hepatotoxicity (SH) during antiretroviral treatment (ART). Methods: Seven hundred fifty-five …

The goal of this study was to investigate clinical outcomes and survival probabilities among
persons coinfected with human immunodeficiency virus (HIV) and human T lymphotropic …

Objective: To evaluate the influence of hepatitis C virus (HCV) coinfection on clinical,
immunological, and virological responses and on adverse reactions to nevirapine …

Human T-cell lymphotropic virus (HTLV) type II has spread among intravenous drug users
(IDUs), many of whom are coinfected with HIV-1. We have investigated the rate of HTLV-II …

According to the latest Department of Health and Human Services guidelines for the use of
antiretroviral therapy (ART) in HIV-1-infected persons, initiation of ART is recommended for …